Mercer Global Advisors
IOVA icon

Mercer Global Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Mercer Global Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$468K Buy
112,611
+94,614
+526% +$359K ﹤0.01% 2359
2026
Q1 		$63.2K Buy
+17,997
New +$57.6K ﹤0.01% 3102

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Mercer Global Advisors's IOVA Position: Q2 2026 in Review

Mercer Global Advisors increased its Iovance Biotherapeutics (IOVA) stake by 526% in Q2 2026, buying an estimated $359K and bringing the position to 112,611 shares worth $468K. The position accounts for ﹤0.01% of the portfolio, ranked #2359.

Mercer Global Advisors first reported a position in IOVA in Q1 2026 and has held it in 2 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Mercer Global Advisors held 112,611 shares of Iovance Biotherapeutics worth $468K as of Q2 2026.
  • Mercer Global Advisors bought 94,614 Iovance Biotherapeutics shares in Q2 2026, an estimated $359K.
  • Iovance Biotherapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2359 holding.
  • Mercer Global Advisors first reported a position in Iovance Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.